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Abstract
Background: Panic disorder affects many people, is associated with a formidable disease burden,
and imposes costs on society. The annual influx of new cases of panic disorder is substantial. From
the public health perspective it may therefore be a sound policy to reduce the influx of new cases,
to maintain the quality of life in many people, and to avoid the economic costs associated with the
full-blown disorder. For this purpose, prevention is needed. Here we present the first economic
evaluation of such an intervention.
Methods:  Randomised trial of 117 people with panic disorder symptoms not meeting the
diagnostic criteria of DSM-IV panic disorder. The interventions were time-limited cognitive-
behavioural therapy v care-as-usual. The central clinical endpoint was DSM-IV panic disorder-free
survival over 3 months. Costs were calculated from the societal perspective. Using the bootstrap
method, incremental cost-effectiveness ratios were obtained, placed in 95% confidence intervals,
projected on the cost-effectiveness plane, and presented as acceptability curves.
Results: The median incremental cost-effectiveness ratio is €6,198 (95% CI 2,435 – 60,731) per
PD-free survival gained, which has a likelihood of 75.2% of being more acceptable from a cost-
effectiveness point of view than care-as-usual when a willingness-to-pay ceiling is assumed of
€10,000 per PD-free survival. The most significant cost driver was therapists' time. A sensitivity
analysis indicated that cost-effectiveness improves when the number of therapist hours is reduced.
Conclusion: This is the first economic evaluation alongside a prevention trial in panic disorder.
The small sample (n = 117) and the short time horizon of 3 months preclude firm conclusions, but
our findings suggest that the intervention may be acceptable from a cost-effectiveness point of view,
especially when therapist involvement can be kept minimal. Nevertheless, our results must await
replication in a larger trial with longer follow-up times before we can confidently recommend
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implementation of the intervention on a broad scale. In the light of our findings and given the
burden of panic disorder, such a new trial is well worth the effort.
Trial registration: Current Controlled Trials ISRCTN33407455.
Background
Panic disorder (PD) is characterised by a substantial influx
of new cases. This influx occurs at a rate of 780 new (ie,
first-ever) cases per 100,000 person-years in the adult
population of 18 – 65 years in the Netherlands [1]. Their
numbers should be compared with the annual number of
2,200 prevalent cases of PD in the same source population
[2]. Looking at these figures one cannot escape the conclu-
sion that 780/2,200 = 35.5% of the prevalent cases are, in
fact, new cases. This casts doubts on the wisdom of relying
solely on curative treatments directed at full-blown PD
cases, and underscores the importance of prevention
directed at sub-clinical cases, i.e. people with some PD
symptoms who do not meet the diagnostic criteria for the
disorder, and are thus 'at risk' of becoming cases [3]. In
this context, it is worth noting that primary prevention of
mental disorders appears to be a viable option [4].
Both sub-clinical and full-blown forms of panic disorder
are associated with substantial costs due to excessive
health care uptake, patients' out-of-pocket costs and pro-
duction losses. By a conservative estimate, a full-blown
PD case generates costs of about € 10,000 per patient per
year, and a sub-clinical case generates € 6,000, even sur-
passing the costs of, for example, depressive disorder [5-
8]. This suggests that offering preventive interventions for
PD are likely to be cost-effective [9,10].
Against this background it was decided to develop and
evaluate a brief preventive intervention based on cogni-
tive-behavioural therapy (CBT) for panic disorder. Here,
we report on the incremental cost-effectiveness ratio
expressed as costs per PD-free survival time. Therapists'
involvement is a significant cost driver, but can be
brought under some control, for example by reducing the
number of hours they invest in the intervention and by
relying more on self-help on the part of the participants
[11]. The latter can be done with the aid of computers
[12,13]. Therefore, we conducted a sensitivity analysis for
different hypothetical levels of therapist involvement: two
therapists all sessions (high), one therapist all sessions
(medium), one therapist only the first part of each session
(low). To our knowledge this is the first economic evalua-
tion of a preventive intervention in sub-clinical manifes-
tations of panic disorder.
Methods
Design
This study was part of a larger multi-site trial. The larger
trial was described in detail by Meulenbeek and col-
leagues [14]. In the larger trial two groups were recruited:
people with relatively mild manifestations of MINI-DSM-
IV panic disorder (N = 100) and people with sub-clinical
manifestations not meeting the diagnostic criteria (N =
117). Here we limit attention to the latter group: people at
risk of becoming cases of panic disorder. It is worth noting
that the large trial was conducted with randomisation
stratified for both groups. Therefore, one can consider the
subset of people with sub-clinical panic disorder as consti-
tuting a trial within a trial. The study was designed as a
pragmatic trial, mimicking the Dutch health care system
as closely as possible in terms of patient recruitment and
the methods used for intake, offering the intervention,
and monitoring outcomes. Measurements were carried
out at baseline (t0) and after three months (t1). In the
treatment arm an extended follow-up was conducted after
6 months (t2) to monitor effect maintenance over time.
The design was approved by an independent medical eth-
ics committee (METIGG), and the trial was registered at
ISRCTN under number 33407455 before commence-
ment.
Recruitment
Participants were recruited through media announce-
ments and via the internet. People who expressed interest
underwent intake at any of the 17 participating regional
mental health services. Participants had to meet the fol-
lowing criteria for inclusion: age over 18 years, presenting
with symptoms of PD falling below the cut-off of 13 on
the Panic Disorder Severity Scale (PDSS) [15], no current
treatment for PD related complaints, no illness requiring
immediate medical attention, and able to function inde-
pendently as well as in a group. In addition, each of the
candidates received a diagnostic interview with the Mini
International Neuropsychiatric Interview, MINI [16]. This
was done to ascertain the DSM-IV PD status [17], assess
the presence of co-morbid agoraphobia, and to exclude
the presence of major depressive disorder. The partici-
pants had to give written informed consent before enter-
ing the trial. See Figure 1 for the flow of participants
through the trial.Cost Effectiveness and Resource Allocation 2009, 7:8 http://www.resource-allocation.com/content/7/1/8
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Flow of participants through the trial Figure 1
Flow of participants through the trial.
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Power
With n = 139 per condition, the original trial was powered
to detect a clinically relevant difference between the con-
ditions corresponding to a mean standardised difference
score (Cohen's d) of at least 0.35 in a 2-sided test at α =
0.05 and a power of (1-β) = 0.80. However, the present
study is based on only a subset of the data, and is under-
powered. Therefore, we refrain from hypothesis testing.
Instead we present outcomes in probabilistic terms, e.g.
the likelihood (in %) that the intervention is superior to
care-as-usual in terms of avoiding new onsets of panic dis-
order in a cost-effective way.
Randomisation
Concealed randomisation was conducted centrally by an
independent third party who was 'blind' with respect to
the participants. Participants were randomised in blocks
of 2 with equal probability to either care-as-usual (N =
108, of these N = 58 with sub-clinical PD), or to the inter-
vention (N = 109, of these N = 59 with sub-clinical PD).
As said, randomisation was stratified for sub-clinical v
clinical case levels of PD, and also with regard to presence
v  absence of co-occurring agoraphobia. The latter was
done because it was assumed that agoraphobia is a prog-
nostically relevant factor for outcome.
Conditions
The experimental condition was a time-limited cognitive-
behavioural preventive intervention for panic disorder:
the  Don't Panic course [18]. The choice for cognitive-
behavioural therapy (CBT) was based on the understand-
ing that CBT is the most cost-effective intervention for PD
in the curative setting [19,20]. The intervention consisted
of 8 sessions of 2 hours each, followed by one booster ses-
sion, again of 2 hours. The booster session was offered
three months after completion of the course. The course
was offered by a prevention worker and a clinician to
groups of 10 (9 to 12) adults. The prevention workers and
clinicians were all experienced in giving CBT-based inter-
ventions. In addition, they received training in offering
the Don't Panic course, and they were to adhere to the
treatment protocol [18]. Participants received an accom-
panying course book [21]. The intervention was well
structured and consisted of psycho-education about anxi-
ety and panic attacks, changing life-style, managing stress,
relaxation training, cognitive restructuring, interoceptive
exposure and in vivo exposure. Each session consisted of a
review of homework assignments, followed by feedback,
rehearsals, information about the upcoming topic and
practical skill-training. The intervention was extensively
pilot tested before entering the clinical trial stage [22].
The control condition consisted of people randomised to
a waiting list. They entered the waiting list on the under-
standing that they would receive the Don't Panic interven-
tion after 3 (max. 6) months. Waitlisted participants were
free to make use of health services and take medication if
so required. The control condition could therefore be
described as care-as-usual (CAU), but it is CAU with one
exception: people were expecting to receive help for their
PD symptoms in the near future.
Outcome
The central clinical endpoint was DSM-IV panic disorder
status (APA, 1994) at follow-up as measured with the
Mini International Neuropsychiatric Interview, MINI
[16]. In order to monitor effect maintenance over time the
self-report version of Panic Disorder Severity Scale, PDSS-
SR [15] was used to measure severity of panic and agora-
phobic symptoms, which was done at t0, t1 and t2.
Costs
Data on costs were collected with the Trimbos Institute
and institute of Medical Technology Assessment Cost
questionnaire for Psychiatry, TIC-P [23]. The TIC-P was
the most frequently used heath service receipt question-
naire in the Netherlands. It used a self-report format about
resource use in the last four weeks. It also contained a sec-
tion on productivity losses due to absenteeism and work-
ing less efficient while at work but not feeling well. All
costs that were relevant from the societal perspective were
included. These costs can be grouped as follows:
￿ Costs of health service uptake in primary care and out-
patient mental health services, including transport by
ambulance, visits to emergency departments and use of
ECG when tachycardia or myocardial infarction was sus-
pected (see Table 1 for details).
￿ Costs of medication, specifically benzodiazepines, tran-
quilisers and sleep medication (calculated as cost price per
standard daily dose as obtained from the Pharmaceutical
Compass at http://www.fk.cvz.nl, plus 6% value added
tax, multiplied by the number of prescription days, plus
the pharmacist's dispensing costs of €6.45 per prescrip-
tion).
￿ Patients' out-of-pocket costs for making visits to health
services, i.e. costs of travel, parking and time costs (see
Table 1 for details).
￿ Costs related to production losses due to absenteeism
[24,25] and lesser efficiency while at work but not feeling
well [26] were valued at €33.90 per lost hour in paid work
[27] and in the domestic sphere at €8.30 per lost hour,
equivalent to the cost of one hour domestic help [27].
￿ Intervention costs were calculated as the costs of thera-
pists' time (€124 per hour) devoted to the intake (1
hour), 8 sessions plus one booster session (2 hours each),Cost Effectiveness and Resource Allocation 2009, 7:8 http://www.resource-allocation.com/content/7/1/8
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administration and preparation (1 hour per session), the
intervention protocol (€45 per therapist), and the course
book (€25 per participant). A naturalistic study showed
that the number of participants in the Don't Panic courses
was on average ten participants [22]. Accordingly, the per-
participant costs of the intervention were calculated to be
€750.
￿ Because the number of hours invested by therapists in
the intervention was the single largest cost-driver, the per-
patient costs for the hypothetical scenarios when thera-
pists' involvement is reduced to 50% and 25% were calcu-
lated at €375 and €190 for both lower intensity levels,
and these figures were used in the sensitivity analysis.
The costs were calculated in accordance with the pertinent
Dutch guideline [27] and they reflect the full economic
costs of the services. The sum of all costs is called 'total
costs', and is expressed as monthly per capita costs in Euro
(€). The reference year is 2003. For that year, the Organi-
sation for Economic Co-operation and Development
(OECD) equates US$1 with €0.932, taking into account
both the currency exchange rate and the purchasing power
in the US and in the Netherlands (see: http://
www.oecd.org and look for purchasing power parities,
PPPs).
Analyses
All analyses were conducted in agreement with the inten-
tion-to-treat principle [28]. Therefore, all participants
were analysed in the condition to which they were ran-
domised, and missing endpoints at follow-up were
imputed using a regression model with the best available
predictors of outcome and the best predictors for dropout.
The first set of predictors was required to get the most pre-
cise estimates for the missing values, the latter to correct
for bias that may stem from differential loss-to-follow-up
associated with t0 variables [29]. These variables were
identified using logistic regression analyses with MINI PD
status and dropout as the dependent variables, and age,
gender, partner status, employment status were measured
at baseline. With help of these variables missing endpoint
were predicted and the predicted values were used to
replace missing endpoints. The remainder of the analyses
was conducted on the imputed data, in four steps.
First, it was ascertained how many people became a case
of MINI DSM-IV PD in each of the conditions at follow-
up. This was done to assess the risk of becoming a case
conditional on receiving or not receiving the intervention.
The probability of not becoming a PD case is equal to 1-
risk, and this was interpreted as the likelihood of having a
panic disorder-free survival over three months. The incre-
Table 1: Direct medical and direct non-medical costs by health service type
Direct Medical
Costs (in 2003 €)
Direct Non-Medical
Costs (in 2003 €)
Health service type unit cost price a km, P, hrs b cost price c
General practitioner Visit 20.20 1.8 km, 1 h 11.10
Social worker d Contact 45.00 7 km, 3 h 28.50
Physiotherapist Contact 22.75 1,8 km, 2 h 19.40
Private practice psychotherapist Session 76.00 5 km, 2 h 19.90
Regional mental health service Contact 124.00 10 km, 3 h 29.00
General Hospital – Outpatient Visit 56.00 7 km, 3 h 28.50
Mental Hospital – Outpatient Visit 88.00 12 km, 4 h 37.20
Teaching Hospital – Outpatient Visit 100.00 12 km, 3 h 29.30
Transport by ambulance Trip 443.00 - -
Emergency Department Visit 139.00 7 km, 3 h 28.50
Use of ECG e Film 36.33 7 km, 3 h 28.50
Home care Hour 30.70 0 km, 0 h 0.00
Informal care (family, friends) f Hour 8.30 0 km, 0 h 0.00
a Integral unit cost prices [27].
b Based on average distances (in km) and travel + waiting + treatment times (in hrs) for receiving treatment [27].
c Costs of 1 km = € 0.16, parking = €2.50 €, 1 h time = €8.30 [27].
d From DFL 77.00 in 1993, converted into Euro, indexed for 2003 and rounded.
e From http://www.ctg-zaio.nl indexed by 1.10 as suggested by Oostenbrink and colleagues [27].
f Valued as domestic help [27].Cost Effectiveness and Resource Allocation 2009, 7:8 http://www.resource-allocation.com/content/7/1/8
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mental effectiveness was computed as the difference
between the probabilities of PD-free survival.
Second, the mean total costs for each of the conditions
were calculated, both at baseline and follow-up. The pre-
post difference in costs were computed to obtain the
increase (or decrease) of costs over time within each of the
conditions. The incremental cost-effectiveness ratio
(ICER) was subsequently calculated as the incremental
costs for a health gain of a PD-free survival over three
months [30-32].
Third, a scatter plot of 2,500 bootstrapped ICERs on the
cost-effectiveness plane was produced, by repeatedly
drawing a random sample with replacement of size n
from the original trial data (also of size n), computing the
ICER and plotting that ICER on the cost-effectiveness
plane [33]. This helped to produce estimates of the prob-
ability that (i) better health was generated for additional
costs, (ii) that the intervention was inferior relative to the
control condition because less health was produced for
additional costs, (iii) that less health was generated for
less costs, and (iv) that the intervention dominates
because better outcomes were obtained for less costs. The
bootstrap analysis also helped to obtain the median ICER
and its 95% confidence interval. The latter was based on
the 2.5th and 97.5th percentile of the distribution of the
2,500 bootstrapped ICERs.
Finally, we wanted to answer the question whether the
incremental costs were balanced by the heath gains to
such an extent that one would be willing to pay for the
additional costs to receive the additional health gain.
Making such a judgement was complicated by the fact that
the exact willingness to pay (WTP) ceiling for a unit health
gain is an unknown quantity. Instead of relying on a sin-
gle WTP ceiling, a series of ceilings was used to calculate
the probability that the intervention was more acceptable
than care-as-usual from a cost-effectiveness point of view
for each of the WTP ceilings. This was presented as an
ICER acceptability curve [33,34], where increasing WTP
ceilings were placed on the horizontal axis, while the
probability of finding the intervention acceptable from a
cost-effectiveness point of view was placed on the vertical
axis.
All analyses were conducted in Stata [35] and Excel Profes-
sional 2003. Three analysts independently performed the
analyses to cross-check results (see Authors' Contribu-
tions).
Sensitivity analysis
The single most important cost-driver was therapists'
time. It was also a cost-driver that can be brought under
some amount of control, for example by relying more on
(computer-aided) self-help, reducing the number of ses-
sions, or increasing the number of participants. By way of
sensitivity analyses all previous analyses were repeated
under different time-investment scenarios. In the actual
situation 2 therapists participated in all sessions during
the full two-hour session. This is an intensive form of ther-
apist guidance and we refer to the costs in this situation as
'high'. In an alternative hypothetical scenario a single
therapist conducts the sessions, thus avoiding the costs of
the co-therapist. We refer to this scenario as 'medium'.
Finally, one therapist could spend one hour with the
group of participants (not the full two-hours per session),
which would further cut down therapist time. This sce-
nario we call 'low'. The analyses were repeated for the
three scenarios under the assumption that the effective-
ness of the intervention would be reduced when therapist
time was reduced. We will return to this issue later.
Results
Characteristics of the sample
At baseline, no differences were found between the treat-
ment (n = 58) and care-as-usual (n = 59) conditions with
regard to gender (71% female), age (mean 43.16 years,
s.d. = 13.05), years of education (mean 13.72, s.d. = 3.09),
partner status (75% living with a partner) and employ-
ment status (66% had a job). The mean PDSS-SR panic
and agoraphobic symptom severity level in the experi-
mental group was 6.26 (s.d. = 4.00); in the control group
this was 6.01 (s.d. = 3.76), which was not statistically dif-
ferent (mean difference = 0.25, s.e = 0.72, t = 0.34, P =
0.732). It was also checked whether randomisation had
resulted in a balanced distribution of co-morbid depres-
sion, agoraphobia and social phobia across the treatment
conditions, and that this was indeed the case (χ2
(1) =
0.000, P = 1.00; χ2
(1) = 0.031, P = 0.86; χ2
(1) = 0.006, P =
0.94, respectively). Finally, age of onset of panic disorder
symptoms was also evenly distributed across the condi-
tions (mean age of 30.6 and 31.3 years in the control and
treatment conditions respectively; t = 0.34; P = 0.738).
Adherence to the intervention
After each session the therapists registered the attendance
of the participants and ascertained whether they had done
their homework. On the basis of this information, 2 (3%)
of the 59 subjects randomized to the experimental group
did not start the course. Reasons for not starting the course
were either starting another course or lack of time because
of work. Forty-six (78%) subjects of the experimental
group completed the course (completing the course is
defined as attending at least 6 sessions). The main reasons
for not completing the course were of a practical nature
(e.g., work, illness). The mean number of attended ses-
sions was 6.4 sessions. Of the attending participants, 77%
had completed their homework for each session, 21% didCost Effectiveness and Resource Allocation 2009, 7:8 http://www.resource-allocation.com/content/7/1/8
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not complete their homework for 1 session, and 2% for 4
sessions.
Concurrent medication use
There was no significant difference in the use of medica-
tion between the groups at baseline. In the experimental
group 16 (27%) participants used medication at baseline,
1 (2%) started medication during the course and 3 (5%)
stopped using medication. In the control group 28 (48%)
participants used medication at baseline, 2 (3%) started
and 2 (3%) stopped medication in the period between
baseline and T1. Therefore, it is unlikely that the present
findings can be explained by changes in medication use.
Incremental effectiveness
After the intervention, at t1, the intervention group had 51
people not meeting the DSM-IV/MINI criteria for PD. The
probability of PD-free survival over three months was
therefore 51/59 = 0.86. In the care-as-usual group the
probability of PD-free survival was 0.74 (43/58). The
incremental effectiveness was calculated as the difference
between the probabilities of a beneficial outcome in each
of the conditions, i.e. 0.86-0.74 = 0.12. The incremental
effectiveness has been defined as the clinical parameter of
interest in the remainder of this study. Its inverse equalled
the number needed to be treated, NNT, as 1/0.12 = 8.3,
indicating that somewhat more than 8 people with sub-
clinical symptom levels have to become recipients of the
intervention (rather then care-as-usual) to generate a
health gain of one additional PD-free survival over three
months in one of them.
Incremental costs
Table 2 gives an overview of the monthly per capita costs
(means, s.d.) in each of the conditions at t0 and t1. The
base-line costs are presented in the column labelled t0. As
can be seen, the total costs in the care-as-usual group
(mean  €346) are higher than in the treatment group
(mean €222). This indicates that randomisation failed to
produce evenly distributed costs across the conditions at
t0. Closer inspection reveals that this difference is caused
by the higher costs associated with production losses in
the care-as-usual group. In the light of the difference
between the conditions at baseline, we decided to calcu-
late the pre-post differences in the costs in each of the con-
ditions, because it would be wrong to solely focus on the
costs at t1 and to ignore the 'false start' at t0. The pre-post
difference of the total costs in the treatment group is €222
– €255 = -€33. Likewise the pre-post difference in the
care-as-usual group is €346 – €426 = -€80. Finally, the
incremental costs are calculated as the difference between
the conditions, hence €80 – €33 = €47, indicating that
the intervention is associated with somewhat higher
monthly per capita costs than care-as-usual, but this dif-
ference is hardly appreciable from an economic point of
view.
It is worth noting that the costs in the treatment condition
were further reduced at the extended six month follow-up
(t2). These costs were €222 at t0, became €255 at t1, and
then became €197 (s.d. = 351) at t2.
So far we have ignored the intervention costs. These are
€750 per recipient. These costs dominate the incremental
costs of €47 at t1. Therefore, the intervention costs must
be seen as the single most important cost driver. When the
Table 2: Costs (in €, mean and standard deviation) by time (pre, post and difference between pre and post) and by condition 
(treatment, usual care) *
PRE (t0) POST (t1) DIFF (t0–t1)
m s.d. m s.d. m s.d.
TREATMENT
• Service uptake 82 163 63 176 19 107
• Medication 9 16 8 16 <1 6
• Out of pocket 30 48 21 38 9 39
• Product. losses 102 211 163 270 -61 301
Total costs ** 222 300 255 358 -33 355
USUAL CARE
• Service uptake 68 83 45 60 23 86
• Medication 16 20 15 18 1 13
• Out of pocket 26 30 26 35 -1 38
• Product. losses 236 436 339 682 -103 460
Total costs 346 495 426 690 -80 483
INCREMENTAL TOTAL COSTS 47 847
* Numbers may not add up due to rounding. ** Costs of the intervention not included.Cost Effectiveness and Resource Allocation 2009, 7:8 http://www.resource-allocation.com/content/7/1/8
Page 8 of 12
(page number not for citation purposes)
intervention costs are included in the above calculations
then the incremental costs at t1 are €797, €422 and €237
for each of the (hypothetical) intensity levels.
Incremental cost-effectiveness
Substitution of the incremental costs (€797) and the
incremental effects (0.12) in the formula for the incre-
mental costs effectiveness ratio,
indicates that the corresponding mean ICER is €6,642 per
three months PD-free survival time for the factual condi-
tion. The arrhythmic mean may not provide the best esti-
mate for the ICER. Therefore we also present the median
ICER, which is based on the bootstrap distribution of
2,500 simulated ICERs. The median ICER is €6,198,
which has a 95% confidence interval of 2,435 – 60,731,
indicating a large amount of stochastic uncertainty.
Sensitivity analysis
The above analyses were repeated for the hypothetical sce-
narios where therapist time is reduced. Reducing therapist
time is associated with lower incremental costs of €797,
€422 and €237, respectively for the high, medium and
low intensity levels. The literature shows that reducing
therapist time in delivering cognitive-behavioural therapy
(CBT) for panic disorder has only a limited impact on
effectiveness. To illustrate, Kenardy and colleagues [12]
found that 12 sessions of CBT were only somewhat more
effective than 6 sessions. Moreover, they found that 6 ses-
sions of CBT augmented with computer-aided CBT was
almost as good as 12 CBT sessions under the guidance of
a therapist. This appears an interesting option for reduc-
ing therapist's time, while not sacrificing too much by way
of the intervention's efficacy. Nevertheless, we prefer to
make conservative assumptions and assume that the
observed incremental effect of 0.12 will be reduced to
0.09 and 0.06 when therapist involvement is reduced.
This results in mean ICERs of €6,642, €4,689 and €3,950
per three months PD-free survival time for the factual con-
dition and the two hypothetical scenarios. Table 3
presents the median ICERs and their confidence intervals.
The upper limit of the scenario where a single therapist is
only involved in one hour per session could not be calcu-
lated, and was replaced by an infinity sign.
Uncertainty and acceptability
A way to obtain an understanding of the uncertainty is
given in Figure 2. This figure presents a scatter of 2,500
simulated bootstrap ICERs on the cost-effectiveness plane
for each of the intensity levels (left-hand panel). The axes
divide the cost-effectiveness plane into four quadrants.
The vast majority (>87%) of the simulated ICERs fall into
the north-east quadrant for each of the three intensity lev-
els, indicating that better health is produced at additional
costs by the intervention relative to the comparator condi-
tion. This is true for all three scenarios. It is also shown
that the scatter shifts to the south when we move from the
high to the low intensity level of therapist involvement.
This indicates that the intervention gets progressively less
costly in producing health gains when therapists' time is
reduced. At the same time it is shown that the scatters
move slightly to the west, indicating that effectiveness also
diminishes when intensity levels are reduced.
The degree of uncertainty precludes statistically significant
findings, but one way to tackle this problem is to adopt a
probabilistic approach. That is, to present an ICER accept-
ability curve, which gives the probability (in %) that the
treatment is more acceptable from a cost-effectiveness
point of view than its alternative, given various ceilings for
the willingness to pay (WTP) for a PD-free survival of
three months. To illustrate, when the WTP ceiling for a
PD-free period is €10,000, then the intervention has a
probability of 75.2% of being more acceptable than care-
as-usual under factual conditions characterised by high
levels of therapist involvement. For the hypothetical
medium and low levels of therapist involvement, this
probability changes to 82.4% and 75.4%, respectively.
As can be seen, under the WTP ceiling of €10,000 the
acceptability depends greatly on the willingness to pay:
the curve is steep at the lower end of WTP ceilings, but
beyond € 10,000 it becomes flat and is then fairly insen-
sitive to WTP levels. This indicates that a decision-maker's
choice at WTP € 10,000 and over is not surrounded by
much uncertainty, even when the ICERs have broad con-
fidence intervals. Below the €10,000 threshold the con-
clusion about the relative cost-effectiveness of the
intervention depends on the precise WTP ceiling. It also
depends on the intensity level of therapist involvement.
ICER Cost Costs Effect Effect Exp Cnt Exp Cnt =− () ( ) /
Table 3: Incremental cost effectiveness for high, medium and 
low levels of therapists' involvement (in € per PD-free survival 
over 3 months)
High Medium Low
Incremental
• costs €797 €422 €237
• effects 0.12 0.09 0.06
Incremental cost/effect*
• median ICER €6,198 €3,792 €2,511
• upper bound 60,731 40,513 8
• lower bound 2,435 -39,306 -26,548
* Median ICER = 50th percentile of the 2,500 bootstrap replications of 
the ICER
lower and upper bounds = 2.5th and 95.5th percentiles of the 
bootstrap distribution.Cost Effectiveness and Resource Allocation 2009, 7:8 http://www.resource-allocation.com/content/7/1/8
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Discussion
This study was conducted to assess the potential of a time-
limited cognitive behavioural intervention for preventing
onsets in panic disorder in a cost-effective way. From a
larger trial the group at risk of becoming PD cases (n =
117) was selected. Of these 59 participated in the Don't
Panic course, while 58 participants were randomised to a
waiting list with unrestricted access to care-as-usual. The
cost-effectiveness analysis was conducted from the soci-
etal perspective, thus including the direct medical, direct
non-medical and indirect costs. The central clinical out-
come was MINI/DSM-IV panic disorder (PD) free survival
time over three months. Therapists' involvement was the
single most important cost driver, and three intensity lev-
els (high, medium and low) were evaluated, with the high
level corresponding to the factual situation, and the
medium and low levels being presented as hypothetical
scenarios.
Distribution of bootstrapped ICERs (n = 2,500) in the cost-effectiveness plane and ICER acceptability curve for each of the  three intensity levels of therapists' involvement Figure 2
Distribution of bootstrapped ICERs (n = 2,500) in the cost-effectiveness plane and ICER acceptability curve for 
each of the three intensity levels of therapists' involvement.
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Main findings
The data suggest that the Don't Panic course is more suc-
cessful in preventing new onsets of DSM-IV panic disorder
in people with sub-clinical symptoms than a waitlist con-
trol condition with unrestricted access to care-as-usual.
The success rates are 86% in the treatment condition ver-
sus 74% in the care-as-usual condition, yielding a differ-
ence of 12% in favour of the intervention.
Not only is the incidence of a disabling disorder reduced,
but this is achieved on average for €6,642 (median
€6,198) per PD-free survival over three months. It can be
concluded that there is a probability larger than 75% that
the intervention is more acceptable from a cost-effective-
ness point of view than care-as-usual when the willingness
to pay (WTP) for a PD-free survival time of three months
has a ceiling of €10,000. Beyond that ceiling, the likeli-
hood that the intervention must be regarded as acceptable
from the health economic point of view remains high and
is not surrounded by doubt. However, below the WTP
ceiling of €10,000 the acceptability of the intervention
depends crucially on the WTP and is also sensitive to the
level of therapist involvement. In fact, sensitivity analyses
showed that the amount of therapist involvement in the
intervention is an important cost driver. It is also a param-
eter that is under (partial) control of the management of
mental health service offering the intervention. The cost-
effectiveness of the intervention is much improved when
therapist involvement is reduced by a factor 2 and 4. The
median ICERs then become €3,792 and €2,511, even
when taking into account that reduced therapist involve-
ment may be associated with lesser efficacy of the inter-
vention.
Limitations
The findings of this study have to be placed in the context
of its limitations.
First, the study was part of a larger trial and was not pow-
ered to detect statistically significant differences in out-
comes and costs. Therefore we refrained from hypothesis
testing. Instead, we took a probabilistic appraoch indicat-
ing the likelihood (in %) that the intervention is superior
to care-as-usual from a health economic point of view.
Second, the time horizon of the trial was limited to only
three months. This period is too short to draw convincing
conclusions about preventing a disorder with an often
chronic and recurrent course. Moreover, the MINI/DSM-
IV PD status at t1 refers to the last month, but we inter-
preted it as an indicator of PD-free survival over the last
three months. Hence, we may have missed an episode of
PD between t0 and t1. However, it is worth mentioning
that the extended follow-up in the treatment arm of the
trial showed that effects are maintained for at least six
months over a range of clinical outcomes (data not
shown). This strengthens the impression that effects
induced by the intervention persist over time, making it
less likely that some people who were PD free at t1 had
experienced PD between t0 and t1.
Third, the baseline costs were somewhat higher in the
control group as compared with the intervention group.
This difference of €124 was not significant (s.e. = 77.87; t
= -1.59; P = 0.131). Nevertheless, we took care of this
baseline difference in our analysis by subtracting the base-
line difference from the costs at follow-up.
Fourth, in a sensitivity analysis the actual situation was
compared with two hypothetical scenarios. This indicated
how reducing therapist involvement would help to lower
the costs of the intervention and thus improve its cost-
effectiveness. Reducing therapist time could be achieved,
for example, by delegating certain tasks from the therapist
to a computer and offerering adjunctive computer-aided
CBT for panic disorder [12,13]. However, in these scenar-
ios we had to make assumptions of how less therapist
involvement would impact on efficacy. To this end we
reduced the incremental effectiveness from the observed
0.12 to hypothetical values 0.09 and 0.06, but these val-
ues are somewhat arbitrary, and the trade-offs between
costs and effects may have been different from what was
modelled. It is worth mentioning, however, that we made
a conscious decision to make conservative assumptions
about the effect of lesser therapist time on the treatment
response – such that the null-hypothesis of no effect was
strengthened.
In light of these limitations our findings should be inter-
preted with some caution.
Conclusion
This is the first economic evaluation of a preventive inter-
vention in panic disorder. The outcomes are encouraging,
but are based on a small trial with a short follow-up.
Therefore, our principal conclusion is that our findings
must await replication in a larger trial with a longer fol-
low-up before confident recommendations can be made
with regard to the broader implementation of the inter-
vention. It is our recommendation that such a trial should
be conducted in the near future. After all, panic disorder is
a crippling condition associated with reduced quality of
life and has formidable economic ramifications for
patients, the health care system, and society as a whole. To
curb the massive annual influx of new cases of panic dis-
order, to maintain the quality of life in many, and perhaps
to avoid some of the costs associated with the full-blown
disorder we need a cost-effective preventive intervention
for panic disorder. Our data suggest that the Don't Panic
course is likely to be one such candidate, especially whenCost Effectiveness and Resource Allocation 2009, 7:8 http://www.resource-allocation.com/content/7/1/8
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the intervention is offered by one qualified therapist. Still,
a larger replication study is needed to further test this
proposition. Under the current conditions, the Don't Panic
course is perhaps best offered as an economically afforda-
ble first step in a stepped-care approach for PD, thus
allowing people to step up to more intensive forms of
treatment, should that be required.
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